(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
Yesterday, Senesco Technologies (OTCQB:SNTI) reported positive results on its long-awaited cohort 3 in its phase 1b/2a trial for SNS01-T, an apoptosis-inducing cancer treatment being tested for multiple myeloma and diffuse large B-cell lymphoma [DLBCL]. Senesco followers have been awaiting this announcement for months now, and some investors expected a pop in SNTI shares if positive results were reported. They were indeed, though the stock actually reacted negatively, down $0.58 to $4.87 on volume twice above average, a drop of over 10%. What happened? First, some details on the trial and SNS01-T.
Senesco and SNS01-T
The main emphasis of Senesco...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: